WALKER LYERLY: Open Payments
NPI 1912919267 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$507 in 27 payments from 9 companies in 2025. Trend: 2023 $477 · 2024 $330 · 2025 $507
Food & beverage: $507
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 13 | $143 |
| Corium, LLC | 3 | $77 |
| Vanda Pharmaceuticals Inc. | 2 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| Neurocrine BioSciences, Inc. | 1 | $39 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Bausch Health US, LLC | 1 | $23 |
| Tris Pharma Inc | 1 | $17 |
Products named: Qelbree, Azstarys, REXULTI, CAPLYTA, INGREZZA, FANAPT, HETLIOZ, Auvelity.
Industry payments across VA — which companies pay providers there.
